IL164214A0 - Use of interleukin-24 to treat ovarian cancer - Google Patents

Use of interleukin-24 to treat ovarian cancer

Info

Publication number
IL164214A0
IL164214A0 IL16421403A IL16421403A IL164214A0 IL 164214 A0 IL164214 A0 IL 164214A0 IL 16421403 A IL16421403 A IL 16421403A IL 16421403 A IL16421403 A IL 16421403A IL 164214 A0 IL164214 A0 IL 164214A0
Authority
IL
Israel
Prior art keywords
interleukin
ovarian cancer
treat ovarian
treat
cancer
Prior art date
Application number
IL16421403A
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of IL164214A0 publication Critical patent/IL164214A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16421403A 2002-04-11 2003-04-08 Use of interleukin-24 to treat ovarian cancer IL164214A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37170002P 2002-04-11 2002-04-11
PCT/US2003/010508 WO2003087308A2 (en) 2002-04-11 2003-04-08 Use of interleukin-24 to treat ovarian cancer

Publications (1)

Publication Number Publication Date
IL164214A0 true IL164214A0 (en) 2005-12-18

Family

ID=29250728

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16421403A IL164214A0 (en) 2002-04-11 2003-04-08 Use of interleukin-24 to treat ovarian cancer

Country Status (7)

Country Link
US (1) US7323164B2 (en)
EP (1) EP1496925A4 (en)
JP (1) JP2005535575A (en)
AU (1) AU2003223482A1 (en)
CA (1) CA2480176A1 (en)
IL (1) IL164214A0 (en)
WO (1) WO2003087308A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP2000482A1 (en) * 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
IL164214A0 (en) 2002-04-11 2005-12-18 Zymogenetics Inc Use of interleukin-24 to treat ovarian cancer
WO2004060269A2 (en) * 2002-12-23 2004-07-22 The Trustees Of Columbia University In The City Of New York Mda-7 and free radicals in the treatment of cancer
WO2005082396A2 (en) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
US20080286227A1 (en) * 2004-09-21 2008-11-20 Applied Research Systems Ars Holding N.V. Use of Il-17F for the Treatment and/or Prevention of Neurologic Diseases
US20070009484A1 (en) * 2005-02-08 2007-01-11 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
CN100408686C (en) * 2005-11-04 2008-08-06 中国人民解放军第三军医大学 Process for preparing human leucocyte interleukin 24 by genetic engineering and it expressing carrier and engineering bacterium
US20100278775A1 (en) * 2007-08-08 2010-11-04 Her Majesty the Queen in Right of Canada, as Re- presented by the Minister of Agriculture and Agri- Plant Bioreactor For The Production Of Interleukin-24 Cytokine
EP2050458A1 (en) * 2007-10-17 2009-04-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL24 for inducing hyperproliferative or autoimmune cell death
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
KR100355111B1 (en) 1993-10-27 2003-03-03 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 Extraction cDNA Library Manufacturing Method and Uses of Manufactured Library
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
WO1998028425A1 (en) 1996-12-23 1998-07-02 Schering Corporation Mammalian cytokine related to il10
US6190909B1 (en) 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
EP1404359A2 (en) * 2000-12-07 2004-04-07 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
US6902930B2 (en) 2001-08-29 2005-06-07 Vanderbilt University Human Mob-5 (IL-24) receptors and uses thereof
JP2005533000A (en) 2002-03-05 2005-11-04 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Method for enhancing immunity induction involving MDA-7
WO2003082255A2 (en) 2002-04-03 2003-10-09 Novartis Ag Use of mob-5 in pain
IL164214A0 (en) 2002-04-11 2005-12-18 Zymogenetics Inc Use of interleukin-24 to treat ovarian cancer

Also Published As

Publication number Publication date
WO2003087308A3 (en) 2003-12-31
US7323164B2 (en) 2008-01-29
EP1496925A2 (en) 2005-01-19
US20030215388A1 (en) 2003-11-20
CA2480176A1 (en) 2003-10-23
EP1496925A4 (en) 2007-05-30
AU2003223482A1 (en) 2003-10-27
WO2003087308A2 (en) 2003-10-23
JP2005535575A (en) 2005-11-24

Similar Documents

Publication Publication Date Title
EP1667680A4 (en) Combination methods of treating cancer
EP1565187A4 (en) Methods of treating cancer and related methods
EP1663259A4 (en) Compositions and methods for treatment of cancer
EP1689379A4 (en) Methods of treating cancer with hdac inhibitors
HK1204476A1 (en) Compounds and methods for treatment of cancer
IL166475A0 (en) Improved treatment of cancer with glutamine
EP1613308A4 (en) Novel methods for the treatment of cancer
ZA200703472B (en) Microwave treatment of minerals
AU2003226301A8 (en) Method of treating cancer
HK1086573A1 (en) Quinazoline derivatives for treatment of cancer
AU2003256847A8 (en) Method of treating cancer
EP1812596A4 (en) Treatment of cancer and compositions
AU2003212634A8 (en) Compounds useful in the treatment of cancer
IL179129A0 (en) Kit for treatment of cancer
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
IL164214A0 (en) Use of interleukin-24 to treat ovarian cancer
AU2003302822A8 (en) Antibodies to treat cancer
AU2002351374A8 (en) Antibodies to treat cancer
IL164218A0 (en) Use of interleukin-19 to treat ovarian cancer
AU2003241346A8 (en) Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
AU2003231803A8 (en) Treatment of cancer with mefloquire
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
GB0329416D0 (en) Treatment of cancer
EP1646385A4 (en) Use of benzothiopenes to treat and prevent prostate cancer
EP1684795A4 (en) Methods and agents for the treatment of cancer